Jazz and Redx in milestone inhibitor agreement
Jazz Pharmaceuticals and Redx announce that pan-RAF inhibitor will enter clinical development
Read More
Tag: inhibitor
Survey reveals ‘key barriers’ limiting PCSK9is prescribing
Just 6% of cardiologists are currently prescribing PCSK9is, despite 97% believing in their abilities.
Read More
Merck initiates late-stage MS study
The previous Phase II trial met its primary endpoint.
Read More
Boehringer expands IPF pipeline with addition of BBT-877
Under the terms of the deal Bridge Biotherapeutics will receive upfront and near term payments of 45 million Euros and is eligible to receive up to more than 1.1 billion Euros in potential payments.
Read More
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
- Daratumumab becomes first oncology injectable approved for patient administration
- Laigo Bio completes final close of €17m seed financing round
